ONCSQ
vs
S&P 500
ONCSQ
S&P 500
Over the past 12 months, ONCSQ has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +12% growth.
Stocks Performance
ONCSQ vs S&P 500
Performance Gap
ONCSQ vs S&P 500
Performance By Year
ONCSQ vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
OncoSec Medical Inc
Glance View
OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. The company is headquartered in Pennington, New Jersey and currently employs 54 full-time employees. The company went IPO on 2015-05-29. The firm is focused on designing, developing and commercializing therapies and medical approaches for the treatment of cancer. Its core technology platform, ImmunoPulse, is a drug-device therapeutic modality comprised of intertumoral electroporation (EP) delivery devices, such as the OncoSec Medical System (OMS) Electroporation device (OMS EP) device. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The OMS EP device adapts to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. Its lead product candidate, TAVO is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid (TAVO), with plasmid DNA-encoded, IL-12, and is delivered into a tumor using its electroporation device.
